Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE™ study

Yenigün, Mustafa; Honka, Marek

doi:10.1111/j.1742-1241.2008.01973.x

Cited by 25 publications

(30 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The improvements in glycemic control observed in the current study conflict with results from the PREDICTIVE trial [13, 14] but are consistent with those from two US studies [15, 16]. In our study, the treatment persistence rate was significantly higher in the GLA-C group and medication adherence was significantly higher among GLA-S patients.…”

Section: Discussionsupporting

confidence: 89%

“…Similar to the PREDICTIVE trial [13], the prevalence rate of hypoglycemia was lower after switching from insulin glargine to insulin detemir in the Medicare cohort in our study; however, the event rates were similar in both groups. No difference in hypoglycemia was observed in the commercially insured IMPACT ® population.…”

Section: Discussionsupporting

confidence: 77%

“…The “Predictable Results and Experience in Diabetes through Intensification and Control to Target: an International Variability Evaluation” (PREDICTIVE: NCT00659295) study was an observational study designed to evaluate switching from insulin glargine to insulin detemir (primarily with respect to adverse events) in patients with type 1 or T2DM [12]. In a European cohort of patients ( n = 777) in the PREDICTIVE study, there were significant improvements in HbA 1c with fewer hypoglycemic events after switching to insulin detemir [13]. Using the framework of cost-effectiveness analysis, an Asian study based on data from a Korean cohort of the PREDICTIVE study reported reduced total diabetes care costs and increased life expectancy of 0.06 years after switching from insulin glargine to insulin detemir [14].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Much Ado About Nothing? A Real-World Study of Patients with Type 2 Diabetes Switching Basal Insulin Analogs

et al. 2014

View full text Add to dashboard Cite

IntroductionType-2 diabetes mellitus (T2DM) is a progressive disease, and many patients eventually require insulin therapy. This study examined real-world outcomes of switching basal insulin analogs among patients with T2DM.MethodsUsing two large United States administrative claims databases (IMPACT® and Humana®), this longitudinal retrospective study examined two cohorts of adult patients with T2DM. Previously on insulin glargine, Cohort 1 either continued insulin glargine (GLA-C) or switched to insulin detemir (DET-S), while Cohort 2 was previously on insulin detemir, and either continued insulin detemir (DET-C) or switched to insulin glargine (GLA-S). One-year follow-up treatment persistence and adherence, glycated hemoglobin (HbA1c), hypoglycemia events, healthcare utilization and costs were assessed. Selection bias was minimized by propensity score matching between treatment groups within each cohort.ResultsA total of 5,921 patients (mean age 60 years, female 50.0%, HbA1c 8.6%) were included in the analysis (Cohort 1: IMPACT®: n = 536 DET-S matched to n = 2,668 GLA-C; Humana®: n = 256 DET-S matched to n = 1,262 GLA-C; Cohort 2: n = 419 GLA-S matched to n = 780 DET-C), with similar baseline characteristics between treatment groups in each cohort. During 1-year follow-up, in Cohort 1, DET-S patients, when compared with GLA-C patients, had lower treatment persistence/adherence with 33–40% restarting insulin glargine, higher rapid-acting insulin use, worse HbA1c outcomes, significantly higher diabetes drug costs, and similar hypoglycemia rates, health care utilization and total costs. However, in Cohort 2 overall opposite outcomes were observed and only 19.8% GLA-S patients restarted insulin detemir.ConclusionsThis study showed contrasting clinical and economic outcomes when patients with T2DM switched basal insulin analogs, with worse outcomes observed for patients switching from insulin glargine to insulin detemir and improved outcomes when switching from insulin detemir to insulin glargine. Further investigation into the therapeutic interchangeability of insulin glargine and insulin detemir in the real-world setting is needed.Electronic supplementary materialThe online version of this article (doi:10.1007/s12325-014-0120-1) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 77%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Much Ado About Nothing? A Real-World Study of Patients with Type 2 Diabetes Switching Basal Insulin Analogs

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Yenigun et al reported on transition from insulin glargine to insulin detemir as a component of basal-bolus therapy within the PREDICITVE study [38]. Two subcohorts of 751 and 26 patients were defined based on prior basal-bolus treatment with glargine qd or glargine bid respectively, with or without OADs.…”

Section: Insulin Detemir In Basal-bolus Regimensmentioning

confidence: 99%

Long-Acting Insulin Analogs: A Review of “Real-World” Effectiveness in Patients with Type 2 Diabetes

Pollock¹,

Erny-Albrecht²,

Kalsekar³

et al. 2011

CDR

View full text Add to dashboard Cite

A systematic review was conducted to evaluate the effectiveness of initiating insulin treatment with insulin glargine or insulin detemir for type 2 diabetes in a routine clinical practice setting. Medline, EMBASE and Cochrane literature databases were searched to identify published "real world" reports. Studies were included in the review if they reported the following; insulin dose, change in HbA1c, change in body weight and hypoglycemic events. In routine practice, decreases inHbA1c associated with insulin glargine and insulin detemir were variable and ranged between approximately -0.3% to -1.5% depending on prior treatment, but switching to insulin analogs was associated with less weight gain than previously reported. Compared with data reported in published trials, hypoglycemic event rates associated with basal analog insulin use in clinical practice were lower in patients initiating insulin and comparable in patients using basal-bolus regimens. Most patients were treated with low doses of insulin analog administered as once daily injections. In routine clinical practice most patients stopped concomitant use of sulfonylureas when initiating insulin analogs and it is likely that this together with the lower dose of insulin influenced outcomes. Nevertheless, despite initiating insulin therapy, it was also apparent that for many patients in routine clinical practice attainment of glycemic goals remains elusive.

show abstract

“…11,19 While Swinnen et al attempt to justify the rationale behind the twice-daily dosing regimen for detemir in L2T3, a discussion of what has been learned since the design of the study was not provided. Specifically, the authors make no mention of the numerous studies supporting the once-daily use of detemir, including randomized controlled trials and large observational studies 11,16,[19][20][21][22][23][24] and clamp and continuous glucose monitoring studies demonstrating comparable timeaction profiles between detemir and glargine. 25,26 In fact, according to the 2009 American Association of Clinical Endocrinologists=American College of Endocrinology guidelines, ''detemir can be used with 1 injection per day in patients with type 2 diabetes; excellent reproducibility of absorption profile within individuals; possibly less weight gain than with other insulins.''…”

mentioning

confidence: 97%

Response to Swinnen et al.

Moses

Koenen

2010

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE™ study

Abstract: Patients with T1D and T2D may be switched from IGlarg to qd IDet as part of a basal-bolus regimen.

Cited by 25 publications

References 38 publications

Much Ado About Nothing? A Real-World Study of Patients with Type 2 Diabetes Switching Basal Insulin Analogs

Much Ado About Nothing? A Real-World Study of Patients with Type 2 Diabetes Switching Basal Insulin Analogs

Long-Acting Insulin Analogs: A Review of “Real-World” Effectiveness in Patients with Type 2 Diabetes

Response to Swinnen et al.

Contact Info

Product

Resources

About

Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE™ study

Abstract: Patients with T1D and T2D may be switched from IGlarg to qd IDet as part of a basal-bolus regimen.

Cited by 25 publications

References 38 publications

Much Ado About Nothing? A Real-World Study of Patients with Type 2 Diabetes Switching Basal Insulin Analogs

Much Ado About Nothing? A Real-World Study of Patients with Type 2 Diabetes Switching Basal Insulin Analogs

Long-Acting Insulin Analogs: A Review of &#x201C;Real-World&#x201D; Effectiveness in Patients with Type 2 Diabetes

Response to Swinnen et al.

Contact Info

Product

Resources

About

Long-Acting Insulin Analogs: A Review of “Real-World” Effectiveness in Patients with Type 2 Diabetes